marked.bio

Company

GSK

11 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 5 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

dostarlimab 7bevacizumab 2pembrolizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

11 of 37 trials shown

  1. A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

    Not yet recruiting Phase 4 GSK Started 2025Primary completion 2027-01 NCT06897527

    dostarlimab FDA EU

    Documented case of dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with platinu…

    MSI-H / dMMRNeoplasms, Endometrial

  2. A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

    Recruiting Phase 3 GSK Started 2026Primary completion 2030-05 NCT07684612

    Mocertatug rezetecan (Mo-Rez)carboplatinpaclitaxelgemcitabinepegylated liposomal doxorubicinbevacizumab FDA EU

    …al testing (compliant to local regulations) for tumor and/or germline Breast Cancer Gene (BRCA1 and BRCA2) mutation.

    BRCA1/2 mutationOvarian Neoplasms

  3. A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

    Recruiting Phase 3 GSK Started 2026Primary completion 2030-07 NCT07286266

    Mocertatug rezetecanpaclitaxelpegylated liposomal doxorubicintopotecangemcitabinepembrolizumabbevacizumab FDA EU

    PARPi, in participants with known or suspected deleterious germline or somatic BRCA mutations and who achieved a complete or partial response to platinum-based chemotherapy must have …

    BRCA1/2 mutationOvarian Neoplasms

  4. A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

    Not yet recruiting Phase 3 GSK Started 2026Primary completion 2029-12 NCT07740720

    dostarlimab FDA EU

    …MR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of 1 or more proteins indicates dMMR

    MSI-H / dMMRNeoplasms, Rectal

  5. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    Recruiting Phase 3 GSK Started 2023Primary completion 2029-03 NCT05855200

    dostarlimab FDA EUCAPEOXFOLFOX

    Has a tumor demonstrating the presence of either dMMR status or MSI-H

    MSI-H / dMMRColonic Neoplasms, Neoplasms, Colon

  6. A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

    Recruiting Phase 2 GSK Started 2025Primary completion 2030-03 NCT07108270

    dostarlimab FDA EUcarboplatinpaclitaxel

    …molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.

    MSI-H / dMMRNeoplasms, Endometrial

  7. A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

    Recruiting Phase 1/2 GSK Started 2025Primary completion 2028-09 NCT07213609

    GSK5460025

    …lt Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

    MSI-H / dMMRNeoplasms, Colorectal, Neoplasms

  8. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

    Active, not recruiting Phase 1/2 GSK Started 2024Primary completion 2026-06 NCT06710847

    GSK4418959PD-1 inhibitor

    …lt Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)

    MSI-H / dMMRNeoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer

  9. A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

    Active, not recruiting Phase 2 GSK Started 2024Primary completion 2027-10 NCT06640049

    dostarlimab FDA EU

    Participant has a tumor which can be categorized as dMMR or MSI-H by central assessment

    MSI-H / dMMRNeoplasms, Rectal

  10. A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

    Active, not recruiting Phase 2 GSK Started 2023Primary completion 2026-11 NCT05723562

    dostarlimab FDA EU

    Participant has a tumor which can be categorized as dMMR or MSI-H by local or central assessment

    MSI-H / dMMRNeoplasms, Rectal

  11. Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

    Active, not recruiting Phase 1 GSK Started 2016Primary completion 2026-05 NCT02715284

    dostarlimab FDA EU

    …ib, ceritinib or experimental) 4) Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers and gastrointestinal cancers, who have received p…

    MSI-H / dMMRNeoplasms